GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) is a prominent player in India’s pharmaceutical industry and is part of the global pharmaceutical giant GlaxoSmithKline (GSK). The company offers a diverse portfolio, including prescription medicines, vaccines, and over-the-counter (OTC) products, focusing on various therapeutic areas such as respiratory, dermatology, anti-infectives, and oncology.
GSK Pharma has a well-established presence across India, leveraging a broad distribution network and strong brand recognition. Its market share in key therapeutic segments further solidifies its leadership position in the Indian pharmaceutical sector. Recent developments include the company’s efforts to expand its product portfolio and strengthen its market position through strategic partnerships and acquisitions. This aligns with GSK’s global strategy of driving innovation and improving access to healthcare solutions worldwide.
The company’s dedication to healthcare innovation, combined with its strategic expansions, continues to make it a significant force in the Indian and global markets.
Latest News on Glaxosmithkline Pharmaceuticals Ltd
Granules India, a subsidiary of GlaxoSmithKline Pharmaceuticals (GSK Pharma), recently received U.S. FDA approval for its generic version of Bupropion Hydrochloride Extended-Release Tablets. This approval includes three dosage strengths: 100 mg, 150 mg, and 200 mg, and these tablets are considered therapeutically equivalent to GSK’s branded product, Wellbutrin SR. Bupropion is commonly used to treat major depressive disorder and seasonal affective disorder, making this approval a significant development for both Granules India and the broader pharmaceutical market.
This FDA approval reflects Granules India’s growing capability in developing and distributing complex generics, allowing the company to expand its presence in the U.S. market while providing cost-effective alternatives for patients needing this medication. The approval is expected to contribute positively to the company’s growth and bolster its position as a key player in the global pharmaceutical industry.
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | |
| Promoters + | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs + | 2.50% | 2.93% | 3.48% | 4.02% | 4.36% |
| DIIs + | 10.01% | 8.64% | 7.90% | 7.51% | 7.34% |
| Government + | 0.01% | 0.01% | 0.00% | 0.00% | 0.00% |
| Public + | 12.48% | 13.42% | 13.62% | 13.48% | 13.30% |
| No. of Shareholders | 1,15,268 | 1,14,663 | 1,18,994 | 1,18,515 | 1,19,228 |
GSK Pharma’s shareholding pattern from September 2023 to September 2024 highlights a consistent ownership by promoters, maintaining a 75.00% stake throughout this period. The Foreign Institutional Investors (FIIs) have steadily increased their holdings, rising from 2.50% in September 2023 to 4.36% by September 2024, showing growing foreign interest in the company. On the other hand, the Domestic Institutional Investors (DIIs) have reduced their stake from 10.01% in September 2023 to 7.34% by September 2024, reflecting a shift in domestic institutional investment.
The public shareholding remained relatively stable but slightly decreased from 12.48% in September 2023 to 13.30% in September 2024, while the number of shareholders fluctuated, showing a marginal increase, with the total number rising from 1,15,268 to 1,19,228. These trends suggest a gradual shift in ownership structure, with growing foreign investment and reduced domestic institutional participation, while the overall shareholding distribution remained stable for GSK Pharma during this period.
You can buy GSK Pharma shares in India by opening a trading account with a broker. You will need to provide your personal details, such as your PAN number, bank details, and other personal documents. Once the trading account is opened, you can buy GSK Pharma shares using the broker’s online trading platform. You can also buy GSK Pharma shares through a mutual fund or a portfolio management service. Some online platforms to buy shares are Zerodha, Sharekhan, and Upstox.
| When | Maximum Price | Minimum Price |
| November 2024 | 2,744.65 | 2,386.66 |
| December 2024 | 2,772.10 | 2,410.52 |
As we step into November 2024, GSK Pharma is expected to see a maximum price of ₹2,744.65 and a minimum price of ₹2,386.66. Moving into December 2024, the stock is anticipated to reach a maximum of ₹2,772.10 and a minimum of ₹2,410.52. These projections reflect the company’s steady performance and market position in the pharmaceutical sector.
| When | Maximum Price | Minimum Price |
| January 2025 | 2,799.82 | 2,153.71 |
| February 2025 | 2,828.10 | 2,175.46 |
| March 2025 | 2,887.49 | 2,221.15 |
| April 2025 | 2,858.90 | 2,199.16 |
| May 2025 | 2,775.63 | 2,135.10 |
| June 2025 | 2,900.54 | 2,231.18 |
| July 2025 | 2,843.66 | 2,187.43 |
| August 2025 | 2,931.61 | 2,255.09 |
| September 2025 | 2,966.79 | 2,282.15 |
| October 2025 | 3,043.93 | 2,341.48 |
| November 2025 | 3,120.03 | 2,400.02 |
| December 2025 | 3,260.43 | 2,508.02 |
As we move into January 2025, GSK Pharma is expected to reach a maximum price of ₹2,799.82 and a minimum of ₹2,153.71. In February, projections indicate a range of ₹2,828.10 to ₹2,175.46. March may see prices peak at ₹2,887.49 with a minimum of ₹2,221.15. By April, prices could fluctuate between ₹2,858.90 and ₹2,199.16. As we move into May, expectations are set at ₹2,775.63 to ₹2,135.10, while June may range from ₹2,900.54 to ₹2,231.18. In July, prices are anticipated to be between ₹2,843.66 and ₹2,187.43, with August likely reaching a maximum of ₹2,931.61 and a minimum of ₹2,255.09. September could see a range of ₹2,966.79 to ₹2,282.15, and by October, it may trade between ₹3,043.93 and ₹2,341.48. In November, projections suggest a peak of ₹3,120.03 and a minimum of ₹2,400.02. Finally, December could see GSK Pharma reaching ₹3,260.43 at maximum, with a minimum of ₹2,508.02.
| When | Maximum Price | Minimum Price |
| January 2026 | 3,358.24 | 2,583.26 |
| February 2026 | 3,274.29 | 2,518.68 |
| March 2026 | 3,339.77 | 2,569.05 |
| April 2026 | 3,407.93 | 2,621.48 |
| May 2026 | 3,374.19 | 2,595.53 |
| June 2026 | 3,458.54 | 2,660.42 |
| July 2026 | 3,390.73 | 2,608.25 |
| August 2026 | 3,495.60 | 2,688.92 |
| September 2026 | 3,565.51 | 2,742.70 |
| October 2026 | 3,658.21 | 2,814.01 |
| November 2026 | 3,749.67 | 2,884.36 |
| December 2026 | 3,843.41 | 2,956.47 |
| When | Maximum Price | Minimum Price |
| January 2027 | 3,881.84 | 2,986.03 |
| February 2027 | 3,981.38 | 3,062.60 |
| March 2027 | 4,136.65 | 3,182.04 |
| April 2027 | 4,055.54 | 3,119.65 |
| May 2027 | 3,937.42 | 3,028.78 |
| June 2027 | 4,114.60 | 3,165.08 |
| July 2027 | 4,033.92 | 3,103.02 |
| August 2027 | 4,158.68 | 3,198.99 |
| September 2027 | 4,304.24 | 3,310.95 |
| October 2027 | 4,416.15 | 3,397.04 |
| November 2027 | 4,526.55 | 3,481.96 |
| December 2027 | 4,639.71 | 3,569.01 |
| When | Maximum Price | Minimum Price |
| January 2028 | 4,732.51 | 3,640.39 |
| February 2028 | 4,853.85 | 3,733.73 |
| March 2028 | 5,043.16 | 3,879.35 |
| April 2028 | 4,944.27 | 3,803.28 |
| May 2028 | 4,800.26 | 3,692.51 |
| June 2028 | 5,016.27 | 3,858.67 |
| July 2028 | 4,917.92 | 3,783.01 |
| August 2028 | 5,070.02 | 3,900.01 |
| September 2028 | 5,247.47 | 4,036.51 |
| October 2028 | 5,383.90 | 4,141.46 |
| November 2028 | 5,518.50 | 4,245.00 |
| December 2028 | 5,656.46 | 4,351.12 |
| When | Maximum Price | Minimum Price |
| January 2029 | 5,769.59 | 4,438.15 |
| February 2029 | 5,917.53 | 4,551.94 |
| March 2029 | 6,148.31 | 4,729.47 |
| April 2029 | 6,027.76 | 4,636.74 |
| May 2029 | 5,852.19 | 4,501.69 |
| June 2029 | 6,115.54 | 4,704.26 |
| July 2029 | 5,995.63 | 4,612.02 |
| August 2029 | 6,181.06 | 4,754.66 |
| September 2029 | 6,397.40 | 4,921.07 |
| October 2029 | 6,563.73 | 5,049.02 |
| November 2029 | 6,727.82 | 5,175.25 |
| December 2029 | 6,896.02 | 5,304.63 |
| When | Maximum Price | Minimum Price |
| January 2030 | 7,033.94 | 5,410.72 |
| February 2030 | 7,214.29 | 5,549.46 |
| March 2030 | 7,495.65 | 5,765.89 |
| April 2030 | 7,348.68 | 5,652.83 |
| May 2030 | 7,134.64 | 5,488.18 |
| June 2030 | 7,455.70 | 5,735.15 |
| July 2030 | 7,309.51 | 5,622.70 |
| August 2030 | 7,535.57 | 5,796.60 |
| September 2030 | 7,799.32 | 5,999.48 |
| October 2030 | 8,002.10 | 6,155.46 |
| November 2030 | 8,202.15 | 6,309.35 |
| December 2030 | 8,407.21 | 6,467.08 |
As we move into January 2030, GSK Pharma is projected to have a maximum price of ₹7,033.94 and a minimum of ₹5,410.72. February could see prices rising to a maximum of ₹7,214.29 with a minimum of ₹5,549.46. In March, the forecast indicates a peak of ₹7,495.65 and a low of ₹5,765.89. Moving into April, we expect a maximum of ₹7,348.68 and a minimum of ₹5,652.83, followed by May with a maximum of ₹7,134.64 and a minimum of ₹5,488.18.
In June, GSK Pharma may reach a maximum of ₹7,455.70 and a minimum of ₹5,735.15. July’s figures suggest a peak of ₹7,309.51 and a low of ₹5,622.70, while August could see prices at ₹7,535.57 maximum and ₹5,796.60 minimum. In September, expectations rise to a maximum of ₹7,799.32 and a minimum of ₹5,999.48. October might bring a peak of ₹8,002.10 and a minimum of ₹6,155.46, leading to November’s anticipated maximum of ₹8,202.15 and minimum of ₹6,309.35. Finally, December 2030 is projected to see a maximum of ₹8,407.21 and a minimum of ₹6,467.08.
GSK Pharma Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,507 |
| Expenses + | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,511 |
| Operating Profit | 657 | 598 | 762 | 804 | 909 | 995 |
| OPM % | 20% | 20% | 23% | 25% | 26% | 28% |
| Other Income + | -262 | 9 | 1,401 | 103 | -21 | -39 |
| Interest | 6 | 4 | 2 | 2 | 2 | 2 |
| Depreciation | 83 | 79 | 68 | 66 | 70 | 70 |
| Profit before tax | 306 | 525 | 2,093 | 839 | 816 | 885 |
| Tax % | 70% | 32% | 19% | 27% | 28% | |
| Net Profit + | 93 | 358 | 1,695 | 611 | 590 | 640 |
| EPS in Rs | 5.5 | 21.14 | 100.04 | 36.05 | 34.83 | 37.78 |
| Dividend Payout % | 727% | 142% | 90% | 89% | 92% |
GSK Pharma has exhibited a strong financial trajectory over recent years, as indicated by its fiscal results for the year ending March 2024. The company reported sales of ₹3,454 crores, marking an increase from ₹3,252 crores in March 2023. This growth underscores GSK Pharma’s robust market position and operational effectiveness.
Total expenses for the period amounted to ₹2,545 crores, slightly higher than the previous year’s ₹2,447 crores. The operating profit was reported at ₹909 crores, resulting in an operating profit margin (OPM) of 26%, which reflects improved efficiency compared to 25% in the prior year.
However, GSK Pharma experienced fluctuations in other income, reporting a decrease to ₹-21 crores from ₹103 crores the previous year. The company maintained low interest expenses at ₹2 crores, consistent across recent periods, while depreciation remained steady at approximately ₹70 crores.
Profit before tax was recorded at ₹816 crores, a minor decline from ₹839 crores. The tax rate for the fiscal year was approximately 28%, slightly up from 27%. Despite these challenges, net profit stood at ₹590 crores, indicating a resilient performance despite a slight dip from ₹611 crores in March 2023. The earnings per share (EPS) for the year was ₹34.83, compared to ₹36.05 previously. Notably, GSK Pharma maintained a high dividend payout ratio of 92%, reinforcing its commitment to returning value to shareholders.
FAQs
Will GSK Pharma stock price grow in 2024?
Yes, GSK Pharma stock price is expected to grow in 2024. The company’s current share price is around Rs 2,630, and analysts have estimated that GSK Pharma price is expected to reach ₹2,772.10 by the end of 2024.
What future is anticipated for GSK Pharma in 2025?
Analysts expect GSK Pharma’s stock price to reach Rs 3,260.43 by the end of 2025. GSK Pharma focus on innovation and quality is expected to help it maintain its growth in the coming years.
In 2030, GSK Pharma is expected to trade in between ₹5,410.72 and ₹8,407.21.
Also Read
- Bajaj Housing Finance Ltd Share Price Target 2024, 2025 to 2030
- Brigade Enterprises Ltd Share Price Target 2024, 2025 to 2030
- Max Healthcare Institute Ltd Share Price Target 2024, 2025 to 2030
Conclusion
In conclusion, GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) continues to maintain a strong position in India’s pharmaceutical industry, with consistent promoter ownership and increasing foreign investment. The company’s strategic focus on expanding its product portfolio, along with FDA approvals like that of Bupropion Hydrochloride, enhances its market presence. GSK Pharma’s share price projections from 2024 to 2030 reflect steady growth, driven by innovation and strategic partnerships. By 2030, the stock is expected to reach a maximum price of ₹8,407.21, highlighting its long-term potential in the pharmaceutical sector.
What did we learn?
- 1 Latest News on Glaxosmithkline Pharmaceuticals Ltd
- 2 Shareholdings Patterns of Glaxosmithkline Pharmaceuticals Ltd
- 3 How to Buy GSK Pharma’s Shares in India?
- 4 GSK Pharma’s Share Price Prediction 2024 to 2030
- 4.1 GSK Pharma’s Share Price Target for 2024
- 4.2 GSK Pharma’s Share Price Target for 2025
- 4.3 GSK Pharma’s Share Price Prediction for 2026
- 4.4 GSK Pharma’s Share Price Target for 2027
- 4.5 GSK Pharma’s Share Price Prediction for 2028
- 4.6 GSK Pharma’s Share Price Target for 2029
- 4.7 GSK Pharma’s Share Price Prediction for 2030
- 5 GSK Pharma Financial Condition: Last 5 Years
- 6 FAQs
- 7 Conclusion
